42 results on '"Cywes-Bentley C"'
Search Results
2. Failure of a novel surface polysaccharide targeting vaccine to prevent Tritrichomonas foetus infection in beef cattle
- Author
-
Hairgrove, T. B., Thompson, J. A., Rocha, J. N., Vinacur, M., Roberts, C., Pier, G. B., and Cywes-Bentley, C.
- Subjects
embryonic structures ,reproductive and urinary physiology - Abstract
Tritrichomonas foetus (T. foetus) is the causative agent of bovine trichomoniasis that has a major impact on production costs for beef cattle farmers. Immunization strategies to effectively protect against T. foetus are a high priority. T. foetus expresses a surface polysaccharide, beta 1-6 poly-Nacetyl glucosamine (PNAG). A PNAG-specific vaccine has demonstrated protection in pigs and horses. This study attempted to protect pregnant cows from an experimental T. foetus infection by prior vaccination with a PNAG-specific vaccine., American Association of Bovine Practitioners Proceedings of the Annual Conference, 2020
- Published
- 2020
- Full Text
- View/download PDF
3. TARGETING PAN-RESISTANT CYSTIC FIBROSIS BACTERIAL PATHOGENS WITH ANTIBODIES TO A BROADLY CONSERVED SURFACE POLYSACCHARIDE: 317
- Author
-
Skurnik, D., Davis, M. R., Benedetti, D., Moravec, K. L., Cywes-Bentley, C., Roux, D., Traficante, D. C., Walsh, R. L., Maira-Litran, T., Cassidy, S. K., Hermos, C., Martin, T. R., Thakkallapalli, E. L., Vargas, S. O., McAdam, A. J., LiPuma, J. J., Pier, G. B., Goldberg, J. B., and Priebe, G. P.
- Published
- 2011
4. Failure of a novel surface polysaccharide targeting vaccine to prevent Tritrichomonas foetus infection in beef cattle
- Author
-
Hairgrove, T. B., primary, Thompson, J. A., additional, Rocha, J. N., additional, Vinacur, M., additional, Roberts, C., additional, Pier, G. B., additional, and Cywes-Bentley, C., additional
- Published
- 2020
- Full Text
- View/download PDF
5. Antibody-based vaccine for tuberculosis: validation in horse foals challenged with the TB-related pathogen Rhodococcus equi
- Author
-
Cywes-Bentley, C., primary, Rocha, J. N., additional, Bordin, A. I., additional, Vinacur, M., additional, Rehman, S., additional, Zaidi, T.S., additional, Meyer, M., additional, Anthony, S., additional, Lambert, M., additional, Vlock, D. R., additional, Giguère, S., additional, Cohen, N. D., additional, and Pier, G. B., additional
- Published
- 2018
- Full Text
- View/download PDF
6. Staphylococcus epidermidis biofilm lifecycle and its virulence: from plantkonic growth, to biofilm structure and systemic dissemination
- Author
-
França, Ângela Maria Oliveira Sousa, Freitas, Ana Isabel Costa, Carvalhais, Virgínia Maria Dinis, Pérez-Cabezas, B., Correia, A., Cywes-Bentley, C., Maira-Litrán, Tomas, Vilanova, Manuel, Pier, Gerald B., Cerca, Nuno, and Universidade do Minho
- Published
- 2013
7. Staphylococcus epidermidis biofilm dispersal cells : an intermediary phenotype?
- Author
-
França, Ângela Maria Oliveira Sousa, Freitas, Ana Isabel Costa, Carvalhais, Virgínia Maria Dinis, Cywes-Bentley, C., Maira-Litrán, Tomas, Vilanova, Manuel, Cerca, Nuno, and Universidade do Minho
- Subjects
Phagocytosis ,Biofilm detachment ,Gene expression ,Antimicrobial resistance ,S. epidermidis - Published
- 2012
8. The exceptionally broad-based potential of active and passive vaccination targeting the conserved microbial surface polysaccharide PNAG
- Author
-
Skurnik D, Cywes-Bentley C, and Gerald Pier
9. Extended-spectrum antibodies protective against carbapenemase-producing Enterobacteriaceae
- Author
-
Skurnik D, Roux D, Pons S, Guillard T, Lu X, Cywes-Bentley C, and Gerald Pier
10. Poly- β -(1→6)- N -acetyl-D-glucosamine mediates surface attachment, biofilm formation, and biocide resistance in Cutibacterium acnes .
- Author
-
Kaplan JB, Cywes-Bentley C, Pier GB, Yakandawala N, Sailer M, Edwards MS, and Kridin K
- Abstract
Background: The commensal skin bacterium Cutibacterium acnes plays a role in the pathogenesis of acne vulgaris and also causes opportunistic infections of implanted medical devices due to its ability to form biofilms on biomaterial surfaces. Poly- β -(1→6)- N -acetyl-D-glucosamine (PNAG) is an extracellular polysaccharide that mediates biofilm formation and biocide resistance in a wide range of bacterial pathogens. The objective of this study was to determine whether C. acnes produces PNAG, and whether PNAG contributes to C. acnes biofilm formation and biocide resistance in vitro ., Methods: PNAG was detected on the surface of C. acnes cells by fluorescence confocal microscopy using the antigen-specific human IgG1 monoclonal antibody F598. PNAG was detected in C. acnes biofilms by measuring the ability of the PNAG-specific glycosidase dispersin B to inhibit biofilm formation and sensitize biofilms to biocide killing., Results: Monoclonal antibody F598 bound to the surface of C. acnes cells. Dispersin B inhibited attachment of C. acnes cells to polystyrene rods, inhibited biofilm formation by C. acnes in glass and polypropylene tubes, and sensitized C. acnes biofilms to killing by benzoyl peroxide and tetracycline., Conclusion: C. acnes produces PNAG, and PNAG contributes to C. acnes biofilm formation and biocide resistance in vitro . PNAG may play a role in C. acnes skin colonization, biocide resistance, and virulence in vivo ., Competing Interests: JK serves as an advisor for, owns equity in, and receives royalties from Kane Biotech Inc., Winnipeg, Canada. This company is developing antibiofilm applications related to dispersin B. GP is an inventor of intellectual properties (human monoclonal antibody to PNAG and PNAG vaccines) that are licensed by Brigham and Women’s Hospital to Alopexx, Inc., an entity in which GP also holds equity. As an inventor of intellectual properties, GP also has the right to receive a share of licensing-related income (royalties, fees) through Brigham and Women’s Hospital from Alopexx, Inc. GP’s interests were reviewed and are managed by the Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict of interest policies. CC-B is an inventor of intellectual properties (use of human monoclonal antibody to PNAG and use of PNAG vaccines) that are licensed by Brigham and Women’s Hospital to Alopexx, Inc. As an inventor of intellectual properties, CC-B also has the right to receive a share of licensing-related income (royalties, fees) through Brigham and Women’s Hospital from Alopexx, Inc. NY, MS, and ME are employees of Kane Biotech Inc., manufacturer of dispersin B (DispersinB®), and own company stocks and stock options. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Kaplan, Cywes-Bentley, Pier, Yakandawala, Sailer, Edwards and Kridin.)
- Published
- 2024
- Full Text
- View/download PDF
11. A comprehensive synthetic library of poly-N-acetyl glucosamines enabled vaccine against lethal challenges of Staphylococcus aureus.
- Author
-
Tan Z, Yang W, O'Brien NA, Pan X, Ramadan S, Marsh T, Hammer N, Cywes-Bentley C, Vinacur M, Pier GB, Gildersleeve JC, and Huang X
- Subjects
- Animals, Mice, Rabbits, Staphylococcal Vaccines immunology, Staphylococcal Vaccines administration & dosage, Female, Methicillin-Resistant Staphylococcus aureus immunology, Acetylglucosamine immunology, Humans, Epitopes immunology, Mice, Inbred BALB C, Staphylococcal Infections prevention & control, Staphylococcal Infections immunology, Staphylococcal Infections microbiology, Staphylococcus aureus immunology
- Abstract
Poly-β-(1-6)-N-acetylglucosamine (PNAG) is an important vaccine target, expressed on many pathogens. A critical hurdle in developing PNAG based vaccine is that the impacts of the number and the position of free amine vs N-acetylation on its antigenicity are not well understood. In this work, a divergent strategy is developed to synthesize a comprehensive library of 32 PNAG pentasaccharides. This library enables the identification of PNAG sequences with specific patterns of free amines as epitopes for vaccines against Staphylococcus aureus (S. aureus), an important human pathogen. Active vaccination with the conjugate of discovered PNAG epitope with mutant bacteriophage Qβ as a vaccine carrier as well as passive vaccination with diluted rabbit antisera provides mice with near complete protection against infections by S. aureus including methicillin-resistant S. aureus (MRSA). Thus, the comprehensive PNAG pentasaccharide library is an exciting tool to empower the design of next generation vaccines., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
12. A high-throughput sequencing approach identifies immunotherapeutic targets for bacterial meningitis in neonates.
- Author
-
Pons S, Frapy E, Sereme Y, Gaultier C, Lebreton F, Kropec A, Danilchanka O, Schlemmer L, Schrimpf C, Allain M, Angoulvant F, Lecuyer H, Bonacorsi S, Aschard H, Sokol H, Cywes-Bentley C, Mekalanos JJ, Guillard T, Pier GB, Roux D, and Skurnik D
- Subjects
- Animals, Mice, Antibodies, Bacterial, Bacteria genetics, Immunotherapy, High-Throughput Nucleotide Sequencing, Escherichia coli genetics, Meningitis, Bacterial
- Abstract
Background: Worldwide, Escherichia coli is the leading cause of neonatal Gram-negative bacterial meningitis, but full understanding of the pathogenesis of this disease is not yet achieved. Moreover, to date, no vaccine is available against bacterial neonatal meningitis., Methods: Here, we used Transposon Sequencing of saturated banks of mutants (TnSeq) to evaluate E. coli K1 genetic fitness in murine neonatal meningitis. We identified E. coli K1 genes encoding for factors important for systemic dissemination and brain infection, and focused on products with a likely outer-membrane or extra-cellular localization, as these are potential vaccine candidates. We used in vitro and in vivo models to study the efficacy of active and passive immunization., Results: We selected for further study the conserved surface polysaccharide Poly-β-(1-6)-N-Acetyl Glucosamine (PNAG), as a strong candidate for vaccine development. We found that PNAG was a virulence factor in our animal model. We showed that both passive and active immunization successfully prevented and/or treated meningitis caused by E. coli K1 in neonatal mice. We found an excellent opsonophagocytic killing activity of the antibodies to PNAG and in vitro these antibodies were also able to decrease binding, invasion and crossing of E. coli K1 through two blood brain barrier cell lines. Finally, to reinforce the potential of PNAG as a vaccine candidate in bacterial neonatal meningitis, we demonstrated that Group B Streptococcus, the main cause of neonatal meningitis in developed countries, also produced PNAG and that antibodies to PNAG could protect in vitro and in vivo against this major neonatal pathogen., Interpretation: Altogether, these results indicate the utility of a high-throughput DNA sequencing method to identify potential immunotherapy targets for a pathogen, including in this study a potential broad-spectrum target for prevention of neonatal bacterial infections., Fundings: ANR Seq-N-Vaq, Charles Hood Foundation, Hearst Foundation, and Groupe Pasteur Mutualité., Competing Interests: Declaration of interests GBP is an inventor of intellectual properties [human monoclonal antibody to PNAG and PNAG vaccines] that are licensed by Brigham and Women's Hospital to Alopexx, Inc. in which GBP also holds equity. As an inventor of intellectual properties, GBP also has the right to receive a share of licensing-related income (royalties, fees) through Brigham and Women's Hospital from Alopexx, Inc. GBP's interests were reviewed and are managed by the Brigham and Women's Hospital and MGB Healthcare in accordance with their conflict of interest policies. CCB and DS are inventors of intellectual properties [use of human monoclonal antibody to PNAG and use of PNAG vaccines] that are licensed by Brigham and Women's Hospital to Alopexx Inc. As inventors of intellectual properties, they also have the right to receive a share of licensing-related income (royalties, fees) through Brigham and Women's Hospital from Alopexx Inc. All other authors declare they have no competing interests., (Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
13. Experimental Urethral Infection with Neisseria gonorrhoeae.
- Author
-
Waltmann A, Duncan JA, Pier GB, Cywes-Bentley C, Cohen MS, and Hobbs MM
- Abstract
Gonorrhea rates and antibiotic resistance are both increasing. Neisseria gonorrhoeae (Ng) is an exclusively human pathogen and is exquisitely adapted to its natural host. Ng can subvert immune responses and undergoes frequent antigenic variation, resulting in limited immunity and protection from reinfection. Previous gonococcal vaccine efforts have been largely unsuccessful, and the last vaccine to be tested in humans was more than 35 years ago. Advancing technologies and the threat of untreatable gonorrhea have fueled renewed pursuit of a vaccine as a long-term sustainable solution for gonorrhea control. Despite the development of a female mouse model of genital gonococcal infection two decades ago, correlates of immunity or protection remain largely unknown, making the gonococcus a challenging vaccine target. The controlled human urethral infection model of gonorrhea (Ng CHIM) has been used to study gonococcal pathogenesis and the basis of anti-gonococcal immunity. Over 200 participants have been inoculated without serious adverse events. The Ng CHIM replicates the early natural course of urethral infection. We are now at an inflexion point to pivot the use of the model for vaccine testing to address the urgency of improved gonorrhea control. Herein we discuss the need for gonorrhea vaccines, and the advantages and limitations of the Ng CHIM in accelerating the development of gonorrhea vaccines., (© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.)
- Published
- 2022
- Full Text
- View/download PDF
14. Immunization against a Conserved Surface Polysaccharide Stimulates Bovine Antibodies with Opsonic Killing Activity but Does Not Protect against Babesia bovis Challenge.
- Author
-
Taus NS, Cywes-Bentley C, Johnson WC, Pier GB, Fry LM, Mousel MR, and Ueti MW
- Abstract
Arthropod-borne apicomplexan pathogens remain a great concern and challenge for disease control in animals and humans. In order to prevent Babesia infection, the discovery of antigens that elicit protective immunity is essential to establish approaches to stop disease dissemination. In this study, we determined that poly-N-acetylglucosamine (PNAG) is conserved among tick-borne pathogens including B. bovis , B. bigemina , B. divergens , B. microti, and Babesia WA1. Calves immunized with synthetic ß-(1→6)-linked glucosamine oligosaccharides conjugated to tetanus toxoid (5GlcNH
2 -TT) developed antibodies with in vitro opsonophagocytic activity against Staphylococcus aureus . Sera from immunized calves reacted to B. bovis . These results suggest strong immune responses against PNAG. However, 5GlcNH2 -TT-immunized bovines challenged with B. bovis developed acute babesiosis with the cytoadhesion of infected erythrocytes to brain capillary vessels. While this antigen elicited antibodies that did not prevent disease, we are continuing to explore other antigens that may mitigate these vector-borne diseases for the cattle industry.- Published
- 2021
- Full Text
- View/download PDF
15. Randomized, controlled trial comparing Rhodococcus equi and poly-N-acetyl glucosamine hyperimmune plasma to prevent R equi pneumonia in foals.
- Author
-
Kahn SK, Cywes-Bentley C, Blodgett GP, Canaday NM, Turner-Garcia CE, Flores-Ahlschwede P, Metcalfe LL, Nevill M, Vinacur M, Sutter PJ, Meyer SC, Bordin AI, Pier GB, and Cohen ND
- Subjects
- Acetylglucosamine, Animals, Antibodies, Bacterial, Horses, Actinomycetales Infections prevention & control, Actinomycetales Infections veterinary, Horse Diseases prevention & control, Pneumonia, Bacterial prevention & control, Pneumonia, Bacterial veterinary, Rhodococcus equi
- Abstract
Background: Hyperimmune plasma raised against β-1→6-poly-N-acetyl glucosamine (PNAG HIP) mediates more opsonophagocytic killing of Rhodococcus equi (R equi) than does R equi hyperimmune plasma (RE HIP) in vitro. The relative efficacy of PNAG HIP and RE HIP to protect foals against R equi pneumonia, however, has not been evaluated., Hypothesis: Transfusion with PNAG HIP will be superior to RE HIP in foals for protection against R equi pneumonia in a randomized, controlled, blinded clinical trial., Animals: Four hundred sixty Quarter Horse and Thoroughbred foals at 5 large breeding farms in the United States., Methods: A randomized, controlled, blinded clinical trial was conducted in which foals were transfused within 24 hours after birth with 2 L of either RE HIP or PNAG HIP. Study foals were monitored through weaning for clinical signs of pneumonia by farm veterinarians. The primary outcome was the proportion of foals that developed pneumonia after receiving each type of plasma., Results: The proportion of foals that developed pneumonia was the same between foals transfused with RE HIP (14%; 32/228) and PNAG HIP (14%; 30/215)., Conclusions and Clinical Importance: Results indicate that PNAG HIP was not superior to a commercially available, United States Department of Agriculture-licensed RE HIP product for protecting foals against R equi pneumonia under field conditions., (© 2021 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.)
- Published
- 2021
- Full Text
- View/download PDF
16. Serum Antibody Activity against Poly- N -Acetyl Glucosamine (PNAG), but Not PNAG Vaccination Status, Is Associated with Protecting Newborn Foals against Intrabronchial Infection with Rhodococcus equi.
- Author
-
Cohen ND, Kahn SK, Cywes-Bentley C, Ramirez-Cortez S, Schuckert AE, Vinacur M, Bordin AI, and Pier GB
- Subjects
- Acetylglucosamine immunology, Actinomycetales Infections blood, Actinomycetales Infections microbiology, Actinomycetales Infections prevention & control, Animals, Animals, Newborn blood, Animals, Newborn immunology, Animals, Newborn microbiology, Antibodies, Bacterial immunology, Bacterial Vaccines immunology, Female, Horse Diseases blood, Horse Diseases immunology, Horse Diseases microbiology, Horses, Male, Pneumonia blood, Pneumonia microbiology, Pneumonia prevention & control, Rhodococcus equi genetics, Vaccination, Acetylglucosamine administration & dosage, Actinomycetales Infections veterinary, Antibodies, Bacterial blood, Bacterial Vaccines administration & dosage, Horse Diseases prevention & control, Pneumonia veterinary, Rhodococcus equi physiology
- Abstract
Rhodococcus equi is a prevalent cause of pneumonia in foals worldwide. Our laboratory has demonstrated that vaccination against the surface polysaccharide β-1→6-poly- N -acetylglucosamine (PNAG) protects foals against intrabronchial infection with R. equi when challenged at age 28 days. However, it is important that the efficacy of this vaccine be evaluated in foals when they are infected at an earlier age, because foals are naturally exposed to virulent R. equi in their environment from birth and because susceptibility is inversely related to age in foals. Using a randomized, blind experimental design, we evaluated whether maternal vaccination against PNAG protected foals against intrabronchial infection with R. equi 6 days after birth. Vaccination of mares per se did not significantly reduce the incidence of pneumonia in foals; however, activities of antibody against PNAG or for deposition of complement component 1q onto PNAG was significantly ( P < 0.05) higher among foals that did not develop pneumonia than among foals that developed pneumonia. Results differed between years, with evidence of protection during 2018 but not 2020. In the absence of a licensed vaccine, further evaluation of the PNAG vaccine is warranted, including efforts to optimize the formulation and dose of this vaccine. IMPORTANCE Pneumonia caused by R. equi is an important cause of disease and death in foals worldwide for which a licensed vaccine is lacking. Foals are exposed to R. equi in their environment from birth, and they appear to be infected soon after parturition at an age when innate and adaptive immune responses are diminished. Results of this study indicate that higher activity of antibodies recognizing PNAG was associated with protection against R. equi pneumonia, indicating the need for further optimization of maternal vaccination against PNAG to protect foals against R. equi pneumonia.
- Published
- 2021
- Full Text
- View/download PDF
17. Antibody activities in hyperimmune plasma against the Rhodococcus equi virulence -associated protein A or poly-N-acetyl glucosamine are associated with protection of foals against rhodococcal pneumonia.
- Author
-
Kahn SK, Cywes-Bentley C, Blodgett GP, Canaday NM, Turner-Garcia CE, Vinacur M, Cortez-Ramirez SC, Sutter PJ, Meyer SC, Bordin AI, Vlock DR, Pier GB, and Cohen ND
- Subjects
- Actinomycetales Infections immunology, Actinomycetales Infections microbiology, Actinomycetales Infections prevention & control, Animals, Animals, Newborn immunology, Animals, Newborn microbiology, Antibodies, Bacterial immunology, Female, Horse Diseases immunology, Horse Diseases microbiology, Horses immunology, Horses microbiology, Immunization, Passive methods, Male, Pneumonia, Bacterial immunology, Pneumonia, Bacterial microbiology, Pneumonia, Bacterial prevention & control, Acetylglucosamine immunology, Actinomycetales Infections veterinary, Antibodies, Bacterial therapeutic use, Bacterial Proteins immunology, Horse Diseases prevention & control, Immunization, Passive veterinary, Pneumonia, Bacterial veterinary, Rhodococcus equi immunology
- Abstract
The efficacy of transfusion with hyperimmune plasma (HIP) for preventing pneumonia caused by Rhodococcus equi remains ill-defined. Quarter Horse foals at 2 large breeding farms were randomly assigned to be transfused with 2 L of HIP from adult donors hyperimmunized either with R. equi (RE HIP) or a conjugate vaccine eliciting antibody to the surface polysaccharide β-1→6-poly-N-acetyl glucosamine (PNAG HIP) within 24 hours of birth. Antibody activities against PNAG and the rhodococcal virulence-associated protein A (VapA), and to deposition of complement component 1q (C՛1q) onto PNAG were determined by ELISA, and then associated with either clinical pneumonia at Farm A (n = 119) or subclinical pneumonia at Farm B (n = 114). Data were analyzed using multivariable logistic regression. Among RE HIP-transfused foals, the odds of pneumonia were approximately 6-fold higher (P = 0.0005) among foals with VapA antibody activity ≤ the population median. Among PNAG HIP-transfused foals, the odds of pneumonia were approximately 3-fold (P = 0.0347) and 11-fold (P = 0.0034) higher for foals with antibody activities ≤ the population median for PNAG or C՛1q deposition, respectively. Results indicated that levels of activity of antibodies against R. equi antigens are correlates of protection against both subclinical and clinical R. equi pneumonia in field settings. Among PNAG HIP-transfused foals, activity of antibodies with C՛1q deposition (an indicator of functional antibodies) were a stronger predictor of protection than was PNAG antibody activity alone. Collectively, these findings suggest that the amount and activity of antibodies in HIP (i.e., plasma volume and/or antibody activity) is positively associated with protection against R. equi pneumonia in foals., Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Gerald B. Pier (GBP) is an inventor of intellectual properties [human monoclonal antibody to PNAG and PNAG vaccines] that are licensed by Brigham and Women’s Hospital to Alopexx Vaccine, LLC, an entity in which GBP also holds equity. As an inventor of intellectual properties, GBP also has the right to receive a share of licensing-related income (royalties, fees) through Brigham and Women’s Hospital from Alopexx Vaccine, LLC. GBP’s interests were reviewed and are managed by the Brigham and Women’s Hospital and Partners Health care in accordance with their conflict of interest policies. Colette Cywes-Bentley (CC-B) is an inventor of intellectual properties [use of human monoclonal antibody to PNAG and use of PNAG vaccines] that are licensed by Brigham and Women’s Hospital to Alopexx Vaccine, LLC. As an inventor of intellectual properties, CC-B also has the right to receive a share of licensing-related income (royalties, fees) through Brigham and Women’s Hospital from Alopexx Vaccine, LLC. Daniel R. Vlock is the Chief Executive Officer of ALOPEXX Vaccines and owns the rights to the PNAG vaccine. Dr. Vlock had no role in the design or analysis of the study. SC Meyer and PJ Sutter work for MG Biologics that produced the plasma and thus might have potential earnings; however, they had no part in the design or analysis of the study. Drs. Glenn Blodgett and Nathan Canaday are employees of the 6666 Ranch and Dr. Carly Turner-Garcia is employed by the Lazy E Ranch. Sarah Meyer and Patrick Sutter are employed by Mg Biologics, Inc. and Dr. Daniel Vlock is employed by ALOPEXX Vaccines. The 6666 Ranch, Lazy E Ranch, Mg Biologics, and ALOPEXX provided support in the form of salaries, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2021
- Full Text
- View/download PDF
18. Vaccination of yearling horses against poly-N-acetyl glucosamine fails to protect against infection with Streptococcus equi subspecies equi.
- Author
-
Cohen ND, Cywes-Bentley C, Kahn SM, Bordin AI, Bray JM, Wehmeyer SG, and Pier GB
- Subjects
- Animals, Female, Horse Diseases immunology, Horses, Immunization, Injections, Intramuscular, Male, Streptococcal Infections immunology, Streptococcal Infections microbiology, Acetylglucosamine immunology, Antibodies, Bacterial immunology, Horse Diseases microbiology, Streptococcal Infections veterinary, Streptococcus equi immunology, Vaccination veterinary
- Abstract
Strangles is a common disease of horses with worldwide distribution caused by the bacterium Streptococcus equi subspecies equi (SEE). Although vaccines against strangles are available commercially, these products have limitations in safety and efficacy. The microbial surface antigen β 1→6 poly-N-acetylglucosamine (PNAG) is expressed by SEE. Here we show that intramuscular (IM) injection alone or a combination of IM plus intranasal (IN) immunization generated antibodies to PNAG that functioned to deposit complement and mediate opsonophagocytic killing of SEE ex vivo. However, immunization strategies targeting PNAG either by either IM only injection or a combination of IM and IN immunizations failed to protect yearling horses against infection following contact with infected horses in an experimental setting. We speculate that a protective vaccine against strangles will require additional components, such as those targeting SEE enzymes that degrade or inactivate equine IgG., Competing Interests: Gerald B. Pier is an inventor of intellectual properties [human monoclonal antibody to PNAG and PNAG vaccines] that are licensed by Brigham and Women’s Hospital to Alopexx Vaccine, LLC, and Alopexx Pharmaceuticals, LLC, entities in which GBP also holds equity. As an inventor of intellectual properties, GBP also has the right to receive a share of licensing-related income (royalties, fees) through Brigham and Women’s Hospital from Alopexx Pharmaceuticals, LLC, and Alopexx Vaccine, LLC. GBP’s interests were reviewed and are managed by the Brigham and Women’s Hospital and Partners Healthcare in accordance with their conflict of interest policies. Colette Cywes-Bentley is an inventor of intellectual properties [use of human monoclonal antibody to PNAG and use of PNAG vaccines] that are licensed by Brigham and Women’s Hospital to Alopexx Pharmaceuticals, LLC. As an inventor of intellectual properties, CC-B also has the right to receive a share of licensing-related income (royalties, fees) through Brigham and Women’s Hospital from Alopexx Pharmaceuticals, LLC. The remaining authors have declared no competing interests exist. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2020
- Full Text
- View/download PDF
19. A Conserved Streptococcal Virulence Regulator Controls the Expression of a Distinct Class of M-Like Proteins.
- Author
-
D'Gama JD, Ma Z, Zhang H, Liu X, Fan H, Morris ERA, Cohen ND, Cywes-Bentley C, Pier GB, and Waldor MK
- Subjects
- Animals, Genome, Bacterial genetics, Horses, Mice, Mutation genetics, Streptococcal Infections genetics, Streptococcus equi genetics, Streptococcus equi pathogenicity, Swine, Virulence genetics, Virulence physiology, Virulence Factors genetics, Whole Genome Sequencing, Streptococcal Infections metabolism, Virulence Factors metabolism
- Abstract
Streptococcus equi subspecies zooepidemicus (SEZ) are group C streptococci that are important pathogens of economically valuable animals such as horses and pigs. Here, we found that many SEZ isolates bind to a monoclonal antibody that recognizes poly- N- acetylglucosamine (PNAG), a polymer that is found as a surface capsule-like structure on diverse microbes. A fluorescence-activated cell sorting-based transposon insertion sequencing (Tn-seq) screen, coupled with whole-genome sequencing, was used to search for genes for PNAG biosynthesis. Surprisingly, mutations in a gene encoding an M-like protein, szM , and the adjacent transcription factor, designated sezV , rendered strains PNAG negative. SezV was required for szM expression and transcriptome analysis showed that SezV has a small regulon. SEZ strains with inactivating mutations in either sezV or szM were highly attenuated in a mouse model of infection. Comparative genomic analyses revealed that linked sezV and szM homologues are present in all SEZ, S. equi subspecies equi (SEE), and M18 group A streptococcal (GAS) genomes in the database, but not in other streptococci. The antibody to PNAG bound to a wide range of SEZ, SEE, and M18 GAS strains. Immunochemical studies suggest that the SzM protein may be decorated with a PNAG-like oligosaccharide although an intact oligosaccharide substituent could not be isolated. Collectively, our findings suggest that the szM and sezV loci define a subtype of virulent streptococci and that an antibody to PNAG may have therapeutic applications in animal and human diseases caused by streptococci bearing SzM-like proteins. IMPORTANCE M proteins are surface-anchored virulence factors in group A streptococci, human pathogens. Here, we identified an M-like protein, SzM, and its positive regulator, SezV, in Streptococcus equi subspecies zooepidemicus (SEZ), an important group of pathogens for domesticated animals, including horses and pigs. SzM and SezV homologues were found in the genomes of all SEZ and S. equi subspecies equi and M18 group A streptococcal strains analyzed but not in other streptococci. Mutant SEZ strains lacking either sezV or szM were highly attenuated in a mouse model of infection. Collectively, our findings suggest that SezV-related regulators and the linked SzM family of M-like proteins define a new subset of virulent streptococci., (Copyright © 2019 D’Gama et al.)
- Published
- 2019
- Full Text
- View/download PDF
20. Immunization against poly- N -acetylglucosamine reduces neutrophil activation and GVHD while sparing microbial diversity.
- Author
-
Hülsdünker J, Thomas OS, Haring E, Unger S, Gonzalo Núñez N, Tugues S, Gao Z, Duquesne S, Cywes-Bentley C, Oyardi O, Kirschnek S, Schmitt-Graeff A, Pabst O, Koenecke C, Duyster J, Apostolova P, Blaser MJ, Becher B, Pier GB, Häcker G, and Zeiser R
- Subjects
- Animals, Antibodies, Monoclonal immunology, Bacteria classification, Bacteria drug effects, Female, Graft vs Host Disease immunology, Graft vs Host Disease pathology, Intestines drug effects, Male, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Neutrophil Activation drug effects, Neutrophils drug effects, Neutrophils immunology, Polysaccharides, Bacterial immunology, Antibodies, Monoclonal administration & dosage, Bacteria immunology, Graft vs Host Disease prevention & control, Immunization, Passive methods, Intestines immunology, Neutrophil Activation immunology, Polysaccharides, Bacterial antagonists & inhibitors
- Abstract
Microbial invasion into the intestinal mucosa after allogeneic hematopoietic cell transplantation (allo-HCT) triggers neutrophil activation and requires antibiotic interventions to prevent sepsis. However, antibiotics lead to a loss of microbiota diversity, which is connected to a higher incidence of acute graft-versus-host disease (aGVHD). Antimicrobial therapies that eliminate invading bacteria and reduce neutrophil-mediated damage without reducing the diversity of the microbiota are therefore highly desirable. A potential solution would be the use of antimicrobial antibodies that target invading pathogens, ultimately leading to their elimination by innate immune cells. In a mouse model of aGVHD, we investigated the potency of active and passive immunization against the conserved microbial surface polysaccharide poly- N -acetylglucosamine (PNAG) that is expressed on numerous pathogens. Treatment with monoclonal or polyclonal antibodies to PNAG (anti-PNAG) or vaccination against PNAG reduced aGVHD-related mortality. Anti-PNAG treatment did not change the intestinal microbial diversity as determined by 16S ribosomal DNA sequencing. Anti-PNAG treatment reduced myeloperoxidase activation and proliferation of neutrophil granulocytes (neutrophils) in the ileum of mice developing GVHD. In vitro, anti-PNAG treatment showed high antimicrobial activity. The functional role of neutrophils was confirmed by using neutrophil-deficient LysM
cre Mcl1fl/fl mice that had no survival advantage under anti-PNAG treatment. In summary, the control of invading bacteria by anti-PNAG treatment could be a novel approach to reduce the uncontrolled neutrophil activation that promotes early GVHD and opens a new avenue to interfere with aGVHD without affecting commensal intestinal microbial diversity., Competing Interests: Conflict of interest statement: G.B.P. is an inventor of intellectual properties (human monoclonal antibody to poly-N-acetylglucosamine [PNAG] and PNAG vaccines) that are licensed by Brigham and Women’s Hospital to Alopexx Vaccine, LLC, and OneBiopharma, Inc., entities in which G.B.P. also holds equity. As an inventor of intellectual properties, G.B.P. also has the right to receive a share of licensing-related income (royalties, fees) through Brigham and Women’s Hospital from OneBiopharma, Inc., and Alopexx Vaccine, LLC. G.B.P.’s interests were reviewed and are managed by the Brigham and Women’s Hospital and Partners Healthcare in accordance with their conflict of interest policies. C.C.-B. is an inventor of intellectual properties (use of human monoclonal antibody to PNAG and use of PNAG vaccines) that are licensed by Brigham and Women’s Hospital to OneBiopharma, Inc. As an inventor of intellectual properties, C.C.-B. also has the right to receive a share of licensing-related income (royalties, fees) through Brigham and Women’s Hospital from OneBiopharma, Inc.- Published
- 2019
- Full Text
- View/download PDF
21. In vitro evaluation of complement deposition and opsonophagocytic killing of Rhodococcus equi mediated by poly-N-acetyl glucosamine hyperimmune plasma compared to commercial plasma products.
- Author
-
Folmar CN, Cywes-Bentley C, Bordin AI, Rocha JN, Bray JM, Kahn SK, Schuckert AE, Pier GB, and Cohen ND
- Subjects
- Actinomycetales Infections immunology, Animals, Antibodies, Bacterial blood, Complement C1 immunology, Female, Horse Diseases immunology, Horse Diseases microbiology, Horses immunology, Male, Neutrophils, Plasma immunology, Acetylglucosamine immunology, Actinomycetales Infections veterinary, Rhodococcus equi immunology
- Abstract
Background: The bacterium Rhodococcus equi can cause severe pneumonia in foals. The absence of a licensed vaccine and limited effectiveness of commercial R. equi hyperimmune plasma (RE-HIP) create a great need for improved prevention of this disease., Hypothesis: Plasma hyperimmune to the capsular polysaccharide poly-N-acetyl glucosamine (PNAG) would be significantly more effective than RE-HIP at mediating complement deposition and opsonophagocytic killing (OPK) of R. equi., Animals: Venipuncture was performed on 9 Quarter Horses., Methods: The ability of the following plasma sources to mediate complement component 1 (C1) deposition onto either PNAG or R. equi was determined by ELISA: (1) PNAG hyperimmune plasma (PNAG-HIP), (2) RE-HIP, and (3) standard non-hyperimmune commercial plasma (SP). For OPK, each plasma type was combined with R. equi, equine complement, and neutrophils isolated from horses (n = 9); after 4 hours, the number of R. equi in each well was determined by quantitative culture. Data were analyzed using linear mixed-effects regression with significance set at P < .05., Results: The PNAG-HIP and RE-HIP were able to deposit significantly (P < .05) more complement onto their respective targets than the other plasmas. The mean proportional survival of R. equi opsonized with PNAG-HIP was significantly (P < .05) less (14.7%) than that for SP (51.1%) or RE-HIP (42.2%)., Conclusions and Clinical Importance: Plasma hyperimmune to PNAG is superior to RE-HIP for opsonizing and killing R. equi in vitro. Comparison of these 2 plasmas in field trials is warranted because of the reported incomplete effectiveness of RE-HIP., (© 2019 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.)
- Published
- 2019
- Full Text
- View/download PDF
22. PNAG-specific equine IgG 1 mediates significantly greater opsonization and killing of Prescottella equi (formerly Rhodococcus equi) than does IgG 4/7 .
- Author
-
Rocha JN, Dangott LJ, Mwangi W, Alaniz RC, Bordin AI, Cywes-Bentley C, Lawhon SD, Pillai SD, Bray JM, Pier GB, and Cohen ND
- Subjects
- Actinomycetales Infections immunology, Actinomycetales Infections prevention & control, Age Factors, Animals, Animals, Newborn, Antibodies, Bacterial classification, Antibodies, Bacterial immunology, Horse Diseases immunology, Horse Diseases prevention & control, Horses immunology, Immunoglobulin G classification, Opsonin Proteins, Pneumonia, Bacterial immunology, Pneumonia, Bacterial prevention & control, Acetylglucosamine immunology, Actinomycetales Infections veterinary, Antibodies, Bacterial blood, Complement C1 immunology, Immunoglobulin G blood, Phagocytosis, Rhodococcus equi immunology
- Abstract
Prescottella equi (formerly Rhodococcus equi) is a facultative intracellular bacterial pathogen that causes severe pneumonia in foals 1-6 months of age, whereas adult horses are highly resistant to infection. We have shown that vaccinating pregnant mares against the conserved surface polysaccharide capsule, β-1 → 6-linked poly-N-acetyl glucosamine (PNAG), elicits opsonic killing antibody that transfers via colostrum to foals and protects them against experimental infection with virulent. R. equi. We hypothesized that equine IgG
1 might be more important than IgG4/7 for mediating protection against R. equi infection in foals. To test this hypothesis, we compared complement component 1 (C1) deposition and polymorphonuclear cell-mediated opsonophagocytic killing (OPK) mediated by IgG1 or IgG4/7 enriched from either PNAG hyperimmune plasma (HIP) or standard plasma. Subclasses IgG1 and IgG4/7 from PNAG HIP and standard plasma were precipitated onto a diethylaminoethyl ion exchange column, then further enriched using a protein G Sepharose column. We determined C1 deposition by enzyme-linked immunosorbent assay (ELISA) and estimated OPK by quantitative microbiologic culture. Anti-PNAG IgG1 deposited significantly (P < 0.05) more C1 onto PNAG than did IgG4/7 from PNAG HIP or subclasses IgG1 and IgG4/7 from standard plasma. In addition, IgG1 from PNAG HIP mediated significantly (P < 0.05) greater OPK than IgG4/7 from PNAG HIP or IgG1 and IgG4/7 from standard plasma. Our findings indicate that anti-PNAG IgG1 is a correlate of protection against R. equi in foals, which has important implications for understanding the immunopathogenesis of R. equi pneumonia, and as a tool for assessing vaccine efficacy and effectiveness when challenge is not feasible., (Copyright © 2019 Elsevier Ltd. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
23. PolyGlcNAc-containing exopolymers enable surface penetration by non-motile Enterococcus faecalis.
- Author
-
Ramos Y, Rocha J, Hael AL, van Gestel J, Vlamakis H, Cywes-Bentley C, Cubillos-Ruiz JR, Pier GB, Gilmore MS, Kolter R, and Morales DK
- Subjects
- Bacterial Proteins, Enterococcus faecalis pathogenicity, Extracellular Polymeric Substance Matrix metabolism, Gram-Positive Bacterial Infections, Humans, Polysaccharides, Bacterial metabolism, Enterococcus faecalis metabolism, Extracellular Polymeric Substance Matrix physiology, Polysaccharides, Bacterial physiology
- Abstract
Bacterial pathogens have evolved strategies that enable them to invade tissues and spread within the host. Enterococcus faecalis is a leading cause of local and disseminated multidrug-resistant hospital infections, but the molecular mechanisms used by this non-motile bacterium to penetrate surfaces and translocate through tissues remain largely unexplored. Here we present experimental evidence indicating that E. faecalis generates exopolysaccharides containing β-1,6-linked poly-N-acetylglucosamine (polyGlcNAc) as a mechanism to successfully penetrate semisolid surfaces and translocate through human epithelial cell monolayers. Genetic screening and molecular analyses of mutant strains identified glnA, rpiA and epaX as genes critically required for optimal E. faecalis penetration and translocation. Mechanistically, GlnA and RpiA cooperated to generate uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) that was utilized by EpaX to synthesize polyGlcNAc-containing polymers. Notably, exogenous supplementation with polymeric N-acetylglucosamine (PNAG) restored surface penetration by E. faecalis mutants devoid of EpaX. Our study uncovers an unexpected mechanism whereby the RpiA-GlnA-EpaX metabolic axis enables production of polyGlcNAc-containing polysaccharides that endow E. faecalis with the ability to penetrate surfaces. Hence, targeting carbohydrate metabolism or inhibiting biosynthesis of polyGlcNAc-containing exopolymers may represent a new strategy to more effectively confront enterococcal infections in the clinic., Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: G.B.P. is an inventor of intellectual properties [human monoclonal antibody to PNAG and PNAG vaccines] that are licensed by Brigham and Women's Hospital to Alopexx Vaccine, LLC, and Alopexx Pharmaceuticals, LLC, entities in which GBP also holds equity. As an inventor of intellectual properties, GBP also has the right to receive a share of licensing-related income (royalties, fees) through Brigham and Women's Hospital from Alopexx Pharmaceuticals, LLC, and Alopexx Vaccine, LLC. GBP's interests were reviewed and are managed by the Brigham and Women’s Hospital and Partners Healthcare in accordance with their conflict of interest policies. C.C-B. is an inventor of intellectual properties [use of human monoclonal antibody to PNAG and use of PNAG vaccines] that are licensed by Brigham and Women's Hospital to Alopexx Pharmaceuticals, LLC. As an inventor of intellectual properties, C.C-B also has the right to receive a share of licensing-related income (royalties, fees) through Brigham and Women's Hospital from Alopexx Pharmaceuticals, LLC. J.R.C-R. is co-founder and scientific advisor for Quentis Therapeutics, Inc. The other authors declare no conflict of interest.
- Published
- 2019
- Full Text
- View/download PDF
24. Antibody to Poly-N-acetyl glucosamine provides protection against intracellular pathogens: Mechanism of action and validation in horse foals challenged with Rhodococcus equi.
- Author
-
Cywes-Bentley C, Rocha JN, Bordin AI, Vinacur M, Rehman S, Zaidi TS, Meyer M, Anthony S, Lambert M, Vlock DR, Giguère S, Cohen ND, and Pier GB
- Subjects
- Animals, Animals, Newborn, Horses, Rhodococcus equi, Acetylglucosamine immunology, Actinomycetales Infections immunology, Antibodies, Bacterial immunology, Antigens, Bacterial immunology, Bacterial Vaccines immunology
- Abstract
Immune correlates of protection against intracellular bacterial pathogens are largely thought to be cell-mediated, although a reasonable amount of data supports a role for antibody-mediated protection. To define a role for antibody-mediated immunity against an intracellular pathogen, Rhodococcus equi, that causes granulomatous pneumonia in horse foals, we devised and tested an experimental system relying solely on antibody-mediated protection against this host-specific etiologic agent. Immunity was induced by vaccinating pregnant mares 6 and 3 weeks prior to predicted parturition with a conjugate vaccine targeting the highly conserved microbial surface polysaccharide, poly-N-acetyl glucosamine (PNAG). We ascertained antibody was transferred to foals via colostrum, the only means for foals to acquire maternal antibody. Horses lack transplacental antibody transfer. Next, a randomized, controlled, blinded challenge was conducted by inoculating at ~4 weeks of age ~10(6) cfu of R. equi via intrabronchial challenge. Eleven of 12 (91%) foals born to immune mares did not develop clinical R. equi pneumonia, whereas 6 of 7 (86%) foals born to unvaccinated controls developed pneumonia (P = 0.0017). In a confirmatory passive immunization study, infusion of PNAG-hyperimmune plasma protected 100% of 5 foals against R. equi pneumonia whereas all 4 recipients of normal horse plasma developed clinical disease (P = 0.0079). Antibodies to PNAG mediated killing of extracellular and intracellular R. equi and other intracellular pathogens. Killing of intracellular organisms depended on antibody recognition of surface expression of PNAG on infected cells, along with complement deposition and PMN-assisted lysis of infected macrophages. Peripheral blood mononuclear cells from immune and protected foals released higher levels of interferon-γ in response to PNAG compared to controls, indicating vaccination also induced an antibody-dependent cellular release of this critical immune cytokine. Overall, antibody-mediated opsonic killing and interferon-γ release in response to PNAG may protect against diseases caused by intracellular bacterial pathogens., Competing Interests: Gerald B. Pier is an inventor of intellectual properties [human monoclonal antibody to PNAG and PNAG vaccines] that are licensed by Brigham and Women’s Hospital to Alopexx Vaccine, LLC, and Alopexx Pharmaceuticals, LLC, entities in which GBP also holds equity. As an inventor of intellectual properties, GBP also has the right to receive a share of licensing-related income (royalties, fees) through Brigham and Women’s Hospital from Alopexx Pharmaceuticals, LLC, and Alopexx Vaccine, LLC. GBP’s interests were reviewed and are managed by the Brigham and Women’s Hospital and Partners Healthcare in accordance with their conflict of interest policies. Colette Cywes-Bentley is an inventor of intellectual properties [use of human monoclonal antibody to PNAG and use of PNAG vaccines] that are licensed by Brigham and Women’s Hospital to Alopexx Pharmaceuticals, LLC. As an inventor of intellectual properties, CC-B also has the right to receive a share of licensing-related income (royalties, fees) through Brigham and Women’s Hospital from Alopexx Pharmaceuticals, LLC. Noah D. Cohen has received an unrestricted gift to the EIDL from Alopexx Vaccines, LLC. Daniel Vlock, holds an equity share and potential royalty income from Alopexx Vaccines, LLC for vaccines to PNAG and monoclonal antibody to PNAG from Alopexx Pharmaceuticals, LLC. Mark Meyer holds minority equity shares of Mg Biologics, Inc. Sarah Anthony and McKenzie Lambert are employees of Mg Biologics, Inc.
- Published
- 2018
- Full Text
- View/download PDF
25. Structural basis for antibody targeting of the broadly expressed microbial polysaccharide poly- N -acetylglucosamine.
- Author
-
Soliman C, Walduck AK, Yuriev E, Richards JS, Cywes-Bentley C, Pier GB, and Ramsland PA
- Subjects
- Antibodies, Monoclonal chemistry, Biofilms, Carbohydrate Conformation, Crystallography, X-Ray, Humans, Immunoglobulin Fab Fragments chemistry, Immunoglobulin Fab Fragments immunology, Immunoglobulin G chemistry, Models, Molecular, Polysaccharides, Bacterial chemistry, Protein Conformation, Staphylococcal Infections microbiology, Staphylococcus aureus immunology, Staphylococcus aureus physiology, Antibodies, Monoclonal immunology, Immunoglobulin G immunology, Polysaccharides, Bacterial immunology
- Abstract
In response to the widespread emergence of antibiotic-resistant microbes, new therapeutic agents are required for many human pathogens. A non-mammalian polysaccharide, poly- N -acetyl-d-glucosamine (PNAG), is produced by bacteria, fungi, and protozoan parasites. Antibodies that bind to PNAG and its deacetylated form (dPNAG) exhibit promising in vitro and in vivo activities against many microbes. A human IgG1 mAb (F598) that binds both PNAG and dPNAG has opsonic and protective activities against multiple microbial pathogens and is undergoing preclinical and clinical assessments as a broad-spectrum antimicrobial therapy. Here, to understand how F598 targets PNAG, we determined crystal structures of the unliganded F598 antigen-binding fragment (Fab) and its complexes with N -acetyl-d-glucosamine (GlcNAc) and a PNAG oligosaccharide. We found that F598 recognizes PNAG through a large groove-shaped binding site that traverses the entire light- and heavy-chain interface and accommodates at least five GlcNAc residues. The Fab-GlcNAc complex revealed a deep binding pocket in which the monosaccharide and a core GlcNAc of the oligosaccharide were almost identically positioned, suggesting an anchored binding mechanism of PNAG by F598. The Fab used in our structural analyses retained binding to PNAG on the surface of an antibiotic-resistant, biofilm-forming strain of Staphylococcus aureus Additionally, a model of intact F598 binding to two pentasaccharide epitopes indicates that the Fab arms can span at least 40 GlcNAc residues on an extended PNAG chain. Our findings unravel the structural basis for F598 binding to PNAG on microbial surfaces and biofilms., (© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
26. Immunization with outer membrane vesicles displaying conserved surface polysaccharide antigen elicits broadly antimicrobial antibodies.
- Author
-
Stevenson TC, Cywes-Bentley C, Moeller TD, Weyant KB, Putnam D, Chang YF, Jones BD, Pier GB, and DeLisa MP
- Subjects
- Animals, Bacterial Infections immunology, Bacterial Vaccines immunology, Female, Mice, Mice, Inbred BALB C, Vaccines, Conjugate immunology, Vaccines, Conjugate therapeutic use, beta-Glucans metabolism, Antibodies, Bacterial immunology, Antigens, Surface immunology, Bacteria immunology, Bacterial Infections prevention & control, Bacterial Vaccines therapeutic use, Immunization methods, Transport Vesicles immunology
- Abstract
Many microbial pathogens produce a β-(1→6)-linked poly- N -acetyl-d-glucosamine (PNAG) surface capsule, including bacterial, fungal, and protozoan cells. Broadly protective immune responses to this single conserved polysaccharide antigen in animals are possible but only when a deacetylated poly- N -acetyl-d-glucosamine (dPNAG; <30% acetate) glycoform is administered as a conjugate to a carrier protein. Unfortunately, conventional methods for natural extraction or chemical synthesis of dPNAG and its subsequent conjugation to protein carriers can be technically demanding and expensive. Here, we describe an alternative strategy for creating broadly protective vaccine candidates that involved coordinating recombinant poly- N -acetyl-d-glucosamine (rPNAG) biosynthesis with outer membrane vesicle (OMV) formation in laboratory strains of Escherichia coli The glycosylated outer membrane vesicles (glycOMVs) released by these engineered bacteria were decorated with the PNAG glycopolymer and induced high titers of PNAG-specific IgG antibodies after immunization in mice. When a Staphylococcus aureus enzyme responsible for PNAG deacetylation was additionally expressed in these cells, glycOMVs were generated that elicited antibodies to both highly acetylated PNAG (∼95-100% acetate) and a chemically deacetylated dPNAG derivative (∼15% acetate). These antibodies mediated efficient in vitro killing of two distinct PNAG-positive bacterial species, namely S. aureus and Francisella tularensis subsp. holarctica , and mice immunized with PNAG-containing glycOMVs developed protective immunity against these unrelated pathogens. Collectively, our results reveal the potential of glycOMVs for targeting this conserved polysaccharide antigen and engendering protective immunity against the broad range of pathogens that produce surface PNAG., Competing Interests: Conflict of interest statement: C.C.-B. is an inventor of intellectual properties (use of human mAb to PNAG and use of PNAG vaccines) that are licensed by Brigham and Women’s Hospital to Alopexx Vaccine, LLC, and Alopexx Pharmaceuticals, LLC. As an inventor of intellectual properties, C.C.-B. also has the right to receive a share of licensing-related income (royalties, fees) through Brigham and Women’s Hospital from Alopexx Pharmaceuticals, LLC, and Alopexx Vaccine, LLC. D.P. and M.P.D. have a financial interest in Versatope, Inc., and M.P.D. also has a financial interest in Glycobia, Inc. The interests of D.P. and M.P.D. are reviewed and managed by Cornell University in accordance with their conflict of interest policies. G.B.P. is an inventor of intellectual properties (human mAb to PNAG and PNAG vaccines) that are licensed by Brigham and Women’s Hospital to Alopexx Vaccine, LLC, and Alopexx Pharmaceuticals, LLC, entities, in which G.B.P. also holds equity. As an inventor of intellectual properties, G.B.P. also has the right to receive a share of licensing-related income (royalties, fees) through Brigham and Women’s Hospital from Alopexx Pharmaceuticals, LLC, and Alopexx Vaccine, LLC. The interests of G.B.P. are reviewed and managed by Brigham and Women’s Hospital and Partners Healthcare in accordance with their conflict of interest policies.
- Published
- 2018
- Full Text
- View/download PDF
27. The exceptionally broad-based potential of active and passive vaccination targeting the conserved microbial surface polysaccharide PNAG.
- Author
-
Skurnik D, Cywes-Bentley C, and Pier GB
- Subjects
- Animals, Bacterial Vaccines isolation & purification, Clinical Trials as Topic, Drug Discovery, Fungal Vaccines isolation & purification, Humans, Malaria Vaccines isolation & purification, Acetylglucosamine administration & dosage, Acetylglucosamine immunology, Bacterial Vaccines immunology, Fungal Vaccines immunology, Immunization, Passive methods, Malaria Vaccines immunology, Vaccination methods
- Abstract
A challenging component of vaccine development is the large serologic diversity of protective antigens. Remarkably, there is a conserved surface/capsular polysaccharide, one of the most effective vaccine targets, expressed by a large number of bacterial, fungal and eukaryotic pathogens: poly-N-acetyl glucosamine (PNAG). Natural antibodies to PNAG are poorly effective at mediating in vitro microbial killing or in vivo protection. Removing most of the acetate substituents to produce a deacetylated glycoform, or using synthetic oligosaccharides of poly-β-1-6-linked glucosamine conjugated to carrier proteins, results in vaccines that elicit high levels of broad-based immunity. A fully human monoclonal antibody is highly active in laboratory and preclinical studies and has been successfully tested in a phase-I setting. Both the synthetic oligosaccharide conjugate vaccine and MAb will be further tested in humans starting in 2016; but, even if effective against only a fraction of the PNAG-producing pathogens, a major advance in vaccine-preventable diseases will occur.
- Published
- 2016
- Full Text
- View/download PDF
28. Emergence of Antimicrobial-Resistant Escherichia coli of Animal Origin Spreading in Humans.
- Author
-
Skurnik D, Clermont O, Guillard T, Launay A, Danilchanka O, Pons S, Diancourt L, Lebreton F, Kadlec K, Roux D, Jiang D, Dion S, Aschard H, Denamur M, Cywes-Bentley C, Schwarz S, Tenaillon O, Andremont A, Picard B, Mekalanos J, Brisse S, and Denamur E
- Subjects
- Animals, Anti-Infective Agents adverse effects, Drug Resistance, Multiple, Bacterial drug effects, Escherichia coli drug effects, Escherichia coli Proteins genetics, Genotype, Humans, Mice, Multilocus Sequence Typing, Phylogeny, Drug Resistance, Multiple, Bacterial genetics, Escherichia coli genetics, Genetic Variation
- Abstract
In the context of the great concern about the impact of human activities on the environment, we studied 403 commensal Escherichia coli/Escherichia clade strains isolated from several animal and human populations that have variable contacts to one another. Multilocus sequence typing (MLST) showed a decrease of diversity 1) in strains isolated from animals that had an increasing contact with humans and 2) in all strains that had increased antimicrobial resistance. A specific B1 phylogroup clonal complex (CC87, Institut Pasteur schema nomenclature) of animal origin was identified and characterized as being responsible for the increased antimicrobial resistance prevalence observed in strains from the environments with a high human-mediated antimicrobial pressure. CC87 strains have a high capacity of acquiring and disseminating resistance genes with specific metabolic and genetic determinants as demonstrated by high-throughput sequencing and phenotyping. They are good mouse gut colonizers but are not virulent. Our data confirm the predominant role of human activities in the emergence of antimicrobial resistance in the environmental bacterial strains and unveil a particular E. coli clonal complex of animal origin capable of spreading antimicrobial resistance to other members of microbial communities., (© The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Molecular Biology and Evolution. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
29. Extended-spectrum antibodies protective against carbapenemase-producing Enterobacteriaceae.
- Author
-
Skurnik D, Roux D, Pons S, Guillard T, Lu X, Cywes-Bentley C, and Pier GB
- Subjects
- Animals, Biofilms, Drug Resistance, Bacterial drug effects, Enterobacteriaceae enzymology, Mice, Virulence Factors immunology, Antibodies, Bacterial pharmacology, Bacterial Proteins biosynthesis, Bacterial Proteins genetics, Bacterial Vaccines immunology, Enterobacteriaceae genetics, Enterobacteriaceae Infections microbiology, Enterobacteriaceae Infections prevention & control, beta-Glucans immunology, beta-Lactamases biosynthesis, beta-Lactamases genetics
- Abstract
Background: Carbapenem-resistant Enterobacteriaceae (CRE) are responsible for worldwide outbreaks and antibiotic treatments are problematic. The polysaccharide poly-(β-1,6)-N-acetyl glucosamine (PNAG) is a vaccine target detected on the surface of numerous pathogenic bacteria, including Escherichia coli. Genes encoding PNAG biosynthetic proteins have been identified in two other main pathogenic Enterobacteriaceae, Enterobacter cloacae and Klebsiella pneumoniae. We hypothesized that antibodies to PNAG might be a new therapeutic option for the different pan-resistant pathogenic species of CRE., Methods: PNAG production was detected by confocal microscopy and its role in the formation of the biofilm (for E. cloacae) and as a virulence factor (for K. pneumoniae) was analysed. The in vitro (opsonophagocytosis killing assay) and in vivo (mouse models of peritonitis) activity of antibodies to PNAG were studied using antibiotic-susceptible and -resistant E. coli, E. cloacae and K. pneumoniae. A PNAG-producing strain of Pseudomonas aeruginosa, an organism that does not naturally produce this antigen, was constructed by adding the pga locus to a strain with inactive alg genes responsible for the production of P. aeruginosa alginate. Antibodies to PNAG were tested in vitro and in vivo as above., Results: PNAG is a major component of the E. cloacae biofilm and a virulence factor for K. pneumoniae. Antibodies to PNAG mediated in vitro killing (>50%) and significantly protected mice against the New Delhi metallo-β-lactamase-producing E. coli (P = 0.02), E. cloacae (P = 0.0196) and K. pneumoniae (P = 0.006), against K. pneumoniae carbapenemase (KPC)-producing K. pneumoniae (P = 0.02) and against PNAG-producing P. aeruginosa (P = 0.0013). Thus, regardless of the Gram-negative bacterial species, PNAG expression is the sole determinant of the protective efficacy of antibodies to this antigen., Conclusions: Our findings suggest antibodies to PNAG may provide extended-spectrum antibacterial protective activity., (© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
30. Intestinal Microbiota of Mice Influences Resistance to Staphylococcus aureus Pneumonia.
- Author
-
Gauguet S, D'Ortona S, Ahnger-Pier K, Duan B, Surana NK, Lu R, Cywes-Bentley C, Gadjeva M, Shan Q, Priebe GP, and Pier GB
- Subjects
- Animals, Female, Humans, Interleukins immunology, Lung immunology, Lung microbiology, Male, Mice, Mice, Inbred C57BL, Staphylococcus aureus immunology, Interleukin-22, Gastrointestinal Microbiome, Intestines microbiology, Pneumonia, Staphylococcal immunology, Pneumonia, Staphylococcal microbiology, Staphylococcus aureus physiology
- Abstract
Th17 immunity in the gastrointestinal tract is regulated by the intestinal microbiota composition, particularly the presence of segmented filamentous bacteria (sfb), but the role of the intestinal microbiota in pulmonary host defense is not well explored. We tested whether altering the gut microbiota by acquiring sfb influences the susceptibility to staphylococcal pneumonia via induction of type 17 immunity. Groups of C57BL/6 mice which differed in their intestinal colonization with sfb were challenged with methicillin-resistant Staphylococcus aureus in an acute lung infection model. Bacterial burdens, bronchoalveolar lavage fluid (BALF) cell counts, cell types, and cytokine levels were compared between mice from different vendors, mice from both vendors after cohousing, mice given sfb orally prior to infection, and mice with and without exogenous interleukin-22 (IL-22) or anti-IL-22 antibodies. Mice lacking sfb developed more severe S. aureus pneumonia than mice colonized with sfb, as indicated by higher bacterial burdens in the lungs, lung inflammation, and mortality. This difference was reduced when sfb-negative mice acquired sfb in their gut microbiota through cohousing with sfb-positive mice or when given sfb orally. Levels of type 17 immune effectors in the lung were higher after infection in sfb-positive mice and increased in sfb-negative mice after acquisition of sfb, as demonstrated by higher levels of IL-22 and larger numbers of IL-22(+) TCRβ(+) cells and neutrophils in BALF. Exogenous IL-22 protected mice from S. aureus pneumonia. The murine gut microbiota, particularly the presence of sfb, promotes pulmonary type 17 immunity and resistance to S. aureus pneumonia, and IL-22 protects against severe pulmonary staphylococcal infection., (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)
- Published
- 2015
- Full Text
- View/download PDF
31. Identification of Poly-N-acetylglucosamine as a Major Polysaccharide Component of the Bacillus subtilis Biofilm Matrix.
- Author
-
Roux D, Cywes-Bentley C, Zhang YF, Pons S, Konkol M, Kearns DB, Little DJ, Howell PL, Skurnik D, and Pier GB
- Subjects
- Acetylglucosamine chemistry, Antibodies, Bacterial physiology, Bacterial Proteins chemistry, Bacterial Proteins physiology, Biosynthetic Pathways, Escherichia coli, HL-60 Cells, Humans, Models, Molecular, Opsonin Proteins physiology, Phagocytosis, Polysaccharides, Bacterial, Protein Structure, Tertiary, Acetylglucosamine physiology, Bacillus subtilis physiology, Biofilms
- Abstract
Bacillus subtilis is intensively studied as a model organism for the development of bacterial biofilms or pellicles. A key component is currently undefined exopolysaccharides produced from proteins encoded by genes within the eps locus. Within this locus are four genes, epsHIJK, known to be essential for pellicle formation. We show they encode proteins synthesizing the broadly expressed microbial carbohydrate poly-N-acetylglucosamine (PNAG). PNAG was present in both pellicle and planktonic wild-type B. subtilis cells and in strains with deletions in the epsA-G and -L-O genes but not in strains deleted for epsH-K. Cloning of the B. subtilis epsH-K genes into Escherichia coli with in-frame deletions in the PNAG biosynthetic genes pgaA-D, respectively, restored PNAG production in E. coli. Cloning the entire B. subtilis epsHIJK locus into pga-deleted E. coli, Klebsiella pneumoniae, or alginate-negative Pseudomonas aeruginosa restored or conferred PNAG production. Bioinformatic and structural predictions of the EpsHIJK proteins suggest EpsH and EpsJ are glycosyltransferases (GT) with a GT-A fold; EpsI is a GT with a GT-B fold, and EpsK is an α-helical membrane transporter. B. subtilis, E. coli, and pga-deleted E. coli carrying the epsHIJK genes on a plasmid were all susceptible to opsonic killing by antibodies to PNAG. The immunochemical and genetic data identify the genes and proteins used by B. subtilis to produce PNAG as a significant carbohydrate factor essential for pellicle formation., (© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
32. USA300 and USA500 clonal lineages of Staphylococcus aureus do not produce a capsular polysaccharide due to conserved mutations in the cap5 locus.
- Author
-
Boyle-Vavra S, Li X, Alam MT, Read TD, Sieth J, Cywes-Bentley C, Dobbins G, David MZ, Kumar N, Eells SJ, Miller LG, Boxrud DJ, Chambers HF, Lynfield R, Lee JC, and Daum RS
- Subjects
- Conserved Sequence, Evolution, Molecular, Genetic Complementation Test, Genome, Bacterial, Humans, Sequence Analysis, DNA, Staphylococcal Infections microbiology, Staphylococcus aureus isolation & purification, Virulence Factors genetics, Virulence Factors metabolism, Bacterial Capsules genetics, Bacterial Capsules metabolism, Bacterial Proteins genetics, Bacterial Proteins metabolism, Mutation, Staphylococcus aureus genetics, Staphylococcus aureus metabolism
- Abstract
Unlabelled: The surface capsular polysaccharide (CP) is a virulence factor that has been used as an antigen in several successful vaccines against bacterial pathogens. A vaccine has not yet been licensed against Staphylococcus aureus, although two multicomponent vaccines that contain CP antigens are in clinical trials. In this study, we evaluated CP production in USA300 methicillin-resistant S. aureus (MRSA) isolates that have become the predominant community-associated MRSA clones in the United States. We found that all 167 USA300 MRSA and 50 USA300 methicillin-susceptible S. aureus (MSSA) isolates were CP negative (CP(-)). Moreover, all 16 USA500 isolates, which have been postulated to be the progenitor lineage of USA300, were also CP(-). Whole-genome sequence analysis of 146 CP(-) USA300 MRSA isolates revealed they all carry a cap5 locus with 4 conserved mutations compared with strain Newman. Genetic complementation experiments revealed that three of these mutations (in the cap5 promoter, cap5D nucleotide 994, and cap5E nucleotide 223) ablated CP production in USA300 and that Cap5E75 Asp, located in the coenzyme-binding domain, is essential for capsule production. All but three USA300 MSSA isolates had the same four cap5 mutations found in USA300 MRSA isolates. Most isolates with a USA500 pulsotype carried three of these four USA300-specific mutations, suggesting the fourth mutation occurred in the USA300 lineage. Phylogenetic analysis of the cap loci of our USA300 isolates as well as publicly available genomes from 41 other sequence types revealed that the USA300-specific cap5 mutations arose sequentially in S. aureus in a common ancestor of USA300 and USA500 isolates., Importance: The USA300 MRSA clone emerged as a community-associated pathogen in the United States nearly 20 years ago. Since then, it has rapidly disseminated and now causes health care-associated infections. This study shows that the CP-negative (CP(-)) phenotype has persisted among USA300 isolates and is a universal and characteristic trait of this highly successful MRSA lineage. It is important to note that a vaccine consisting solely of CP antigens would not likely demonstrate high efficacy in the U.S. population, where about half of MRSA isolates comprise USA300. Moreover, conversion of a USA300 strain to a CP-positive (CP(+)) phenotype is unlikely in vivo or in vitro since it would require the reversion of 3 mutations. We have also established that USA300 MSSA isolates and USA500 isolates are CP(-) and provide new insight into the evolution of the USA300 and USA500 lineages., (Copyright © 2015 Boyle-Vavra et al.)
- Published
- 2015
- Full Text
- View/download PDF
33. Microbiota-driven immune cellular maturation is essential for antibody-mediated adaptive immunity to Staphylococcus aureus infection in the eye.
- Author
-
Zaidi T, Zaidi T, Cywes-Bentley C, Lu R, Priebe GP, and Pier GB
- Subjects
- Animals, Bacterial Load, CD4-Positive T-Lymphocytes immunology, Cornea microbiology, Cornea pathology, Disease Models, Animal, Eye Infections microbiology, Humans, Intercellular Adhesion Molecule-1 immunology, Interleukin-17 metabolism, Interleukins metabolism, Mice, Mice, Inbred C57BL, Neutrophils immunology, Interleukin-22, Adaptive Immunity, Antibodies, Bacterial immunology, Eye immunology, Eye Infections immunology, Microbiota immunology, Staphylococcal Infections immunology, Staphylococcus aureus immunology
- Abstract
As an immune-privileged site, the eye, and particularly the outer corneal surface, lacks resident mature immune effector cells. Physical barriers and innate mediators are the best-described effectors of immunity in the cornea. When the barriers are breached, infection can result in rapid tissue destruction, leading to loss of visual acuity and frank blindness. To determine the cellular and molecular components needed for effective adaptive immunity on the corneal surface, we investigated which immune system effectors were required for protection against Staphylococcus aureus corneal infections in mice, which are a serious cause of human eye infections. Both systemically injected and topically applied antibodies to the conserved cell surface polysaccharide poly-N-acetylglucosamine (PNAG) were effective at mediating reductions in corneal pathology and bacterial levels. Additional host factors impacting protection included intercellular adhesion molecule 1 (ICAM-1)-dependent polymorphonuclear leukocyte (PMN) recruitment, functional CD4(+) T cells, signaling via the interleukin-17 (IL-17) receptor, and IL-22 production. In germfree mice, there was no protective efficacy of antibody to PNAG due to the lack of LY6G(+) inflammatory cell coeffector recruitment to the cornea. Protection was manifest after 3 weeks of exposure to conventional mice and acquisition of a resident microbiota. We conclude that in the anterior eye, ICAM-1-mediated PMN recruitment to the infected cornea along with endogenous microbiota-matured CD4(+) T cells producing both IL-17 and IL-22 is required for antibody to PNAG to protect against S. aureus infection., (Copyright © 2014, American Society for Microbiology. All Rights Reserved.)
- Published
- 2014
- Full Text
- View/download PDF
34. A Poly-N-acetylglucosamine-Shiga toxin broad-spectrum conjugate vaccine for Shiga toxin-producing Escherichia coli.
- Author
-
Lu X, Skurnik D, Pozzi C, Roux D, Cywes-Bentley C, Ritchie JM, Munera D, Gening ML, Tsvetkov YE, Nifantiev NE, Waldor MK, and Pier GB
- Subjects
- Animals, Animals, Newborn, Antibodies, Bacterial blood, Antibodies, Neutralizing blood, Antitoxins blood, Disease Models, Animal, Escherichia coli Infections immunology, Escherichia coli Vaccines administration & dosage, Mice, Microbial Viability immunology, Opsonin Proteins blood, Rabbits, Vaccines, Conjugate administration & dosage, Vaccines, Conjugate immunology, Escherichia coli Infections prevention & control, Escherichia coli Vaccines immunology, Shiga Toxin immunology, Shiga-Toxigenic Escherichia coli immunology, beta-Glucans immunology
- Abstract
Many pathogens produce the β-(1-6)-linked poly-N-acetylglucosamine (PNAG) surface polysaccharide that is being developed as a broadly protective antimicrobial vaccine. However, it is unknown whether systemically injected PNAG vaccines or antibodies would provide protective immunity against pathogens confined to the gastrointestinal tract such as Shiga toxin (Stx)-producing Escherichia coli (STEC), an important group of gastrointestinal (GI) pathogens for which effective immunotherapeutics are lacking. To ascertain whether systemic IgG antibody to PNAG impacts this infectious situation, a vaccine consisting of a synthetic nonamer of nonacetylated PNAG, 9GlcNH2, conjugated to the Shiga toxin 1b subunit (9GlcNH2-Stx1b) was produced. Rabbit antibodies raised to the conjugate vaccine were tested for bacterial killing and toxin neutralization in vitro and protection against infection in infant mice. Cell surface PNAG was detected on all 9 STEC isolates tested, representing 6 STEC serogroups, including E. coli O157:H7. Antibody to the 9GlcNH2-Stx1b conjugate neutralized Stx1 potently and Stx2 modestly. For O157:H7 and O104:H4 STEC strains, antibodies elicited by the 9GlcNH2-Stx1b conjugate possessed opsonic killing and bactericidal activity. Following intraperitoneal injection, antibodies to both PNAG and Stx were needed for infant mouse protection against O157 STEC. These antibodies also mediated protection against the Stx2-producing O104:H4 strain that was the cause of a recent outbreak in Germany, although sufficient doses of antibody to PNAG alone were protective against this strain in infant mice. Our observations suggest that vaccination against both PNAG and Stx, using a construct such as the 9GlcNH2-Stx1b conjugate vaccine, would be protective against a broad range of STEC serogroups. IMPORTANCE The presence of poly-N-acetylglucosamine (PNAG) on many pathogens presents an opportunity to target this one structure with a multispecies vaccine. Whether antibodies to PNAG can protect against pathogens confined to the gastrointestinal tract is not known. As Shiga toxin (Stx)-producing Escherichia coli (STEC) bacteria are serious causes of infection whose virulence is dependent on elaboration of Stx, we prepared a vaccine containing a synthetic nonamer of PNAG (9GlcNH2) conjugated to Shiga toxin 1b subunit (9GlcNH2-Stx1b) to evaluate bacterial killing, toxin neutralization, and protective efficacy in infant mice. All nine (100%) clinical strains of STEC from different serogroups expressed PNAG. Vaccine-induced antibody mediated in vitro killing of STEC and neutralization of both Stx1 and Stx2. Passive administration of antibody to the conjugate showed protection requiring immunity to both PNAG and Stx for O157 strains, although for an O104 strain, antibody to PNAG alone was protective. Immunity to PNAG may contribute to protection against STEC infections.
- Published
- 2014
- Full Text
- View/download PDF
35. Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens.
- Author
-
Cywes-Bentley C, Skurnik D, Zaidi T, Roux D, Deoliveira RB, Garrett WS, Lu X, O'Malley J, Kinzel K, Zaidi T, Rey A, Perrin C, Fichorova RN, Kayatani AK, Maira-Litràn T, Gening ML, Tsvetkov YE, Nifantiev NE, Bakaletz LO, Pelton SI, Golenbock DT, and Pier GB
- Subjects
- Animals, Antibodies, Bacterial pharmacology, Antibodies, Monoclonal immunology, Antibodies, Monoclonal pharmacology, Bacterial Capsules immunology, Bacterial Capsules metabolism, Bacterial Infections microbiology, Bacterial Infections prevention & control, Fungi immunology, Fungi physiology, Gram-Negative Bacteria immunology, Gram-Negative Bacteria physiology, Gram-Positive Bacteria immunology, Gram-Positive Bacteria physiology, Host-Pathogen Interactions drug effects, Host-Pathogen Interactions immunology, Humans, Immunoglobulin G immunology, Immunoglobulin G pharmacology, Malaria parasitology, Malaria prevention & control, Mice, Mice, Inbred C57BL, Mycoses microbiology, Mycoses prevention & control, Opsonin Proteins immunology, Plasmodium berghei immunology, Plasmodium berghei physiology, Protein Binding immunology, Staphylococcus aureus metabolism, Survival Analysis, Time Factors, Acetylglucosamine immunology, Antibodies, Bacterial immunology, Bacterial Infections immunology, Malaria immunology, Mycoses immunology, Staphylococcus aureus immunology
- Abstract
Microbial capsular antigens are effective vaccines but are chemically and immunologically diverse, resulting in a major barrier to their use against multiple pathogens. A β-(1→6)-linked poly-N-acetyl-d-glucosamine (PNAG) surface capsule is synthesized by four proteins encoded in genetic loci designated intercellular adhesion in Staphylococcus aureus or polyglucosamine in selected Gram-negative bacterial pathogens. We report that many microbial pathogens lacking an identifiable intercellular adhesion or polyglucosamine locus produce PNAG, including Gram-positive, Gram-negative, and fungal pathogens, as well as protozoa, e.g., Trichomonas vaginalis, Plasmodium berghei, and sporozoites and blood-stage forms of Plasmodium falciparum. Natural antibody to PNAG is common in humans and animals and binds primarily to the highly acetylated glycoform of PNAG but is not protective against infection due to lack of deposition of complement opsonins. Polyclonal animal antibody raised to deacetylated glycoforms of PNAG and a fully human IgG1 monoclonal antibody that both bind to native and deacetylated glycoforms of PNAG mediated complement-dependent opsonic or bactericidal killing and protected mice against local and/or systemic infections by Streptococcus pyogenes, Streptococcus pneumoniae, Listeria monocytogenes, Neisseria meningitidis serogroup B, Candida albicans, and P. berghei ANKA, and against colonic pathology in a model of infectious colitis. PNAG is also a capsular polysaccharide for Neisseria gonorrhoeae and nontypable Hemophilus influenzae, and protects cells from environmental stress. Vaccination targeting PNAG could contribute to immunity against serious and diverse prokaryotic and eukaryotic pathogens, and the conserved production of PNAG suggests that it is a critical factor in microbial biology.
- Published
- 2013
- Full Text
- View/download PDF
36. Poly-N-acetylglucosamine expression by wild-type Yersinia pestis is maximal at mammalian, not flea, temperatures.
- Author
-
Yoong P, Cywes-Bentley C, and Pier GB
- Subjects
- Animals, Biofilms growth & development, Color, Congo Red metabolism, Culture Media chemistry, Flow Cytometry, Microscopy, Confocal, Siphonaptera, Temperature, Yersinia pestis growth & development, Yersinia pestis metabolism, Galactans metabolism, Gene Expression Regulation, Bacterial, Yersinia pestis physiology
- Abstract
Unlabelled: Numerous bacteria, including Yersinia pestis, express the poly-N-acetylglucosamine (PNAG) surface carbohydrate, a major component of biofilms often associated with a specific appearance of colonies on Congo red agar. Biofilm formation and PNAG synthesis by Y. pestis have been reported to be maximal at 21 to 28°C or "flea temperatures," facilitating the regurgitation of Y. pestis into a mammalian host during feeding, but production is diminished at 37°C and thus presumed to be decreased during mammalian infection. Most studies of PNAG expression and biofilm formation by Y. pestis have used a low-virulence derivative of strain KIM, designated KIM6+, that lacks the pCD1 virulence plasmid, and an isogenic mutant without the pigmentation locus, which contains the hemin storage genes that encode PNAG biosynthetic proteins. Using confocal microscopy, fluorescence-activated cell sorter analysis and growth on Congo red agar, we confirmed prior findings regarding PNAG production with the KIM6+ strain. However, we found that fully virulent wild-type (WT) strains KIM and CO92 had maximal PNAG expression at 37°C, with lower PNAG production at 28°C both in broth medium and on Congo red agar plates. Notably, the typical dark colony morphology appearing on Congo red agar was maintained at 28°C, indicating that this phenotype is not associated with PNAG expression in WT Y. pestis. Extracts of WT sylvatic Y. pestis strains from the Russian Federation confirmed the maximal expression of PNAG at 37°C. PNAG production by WT Y. pestis is maximal at mammalian and not insect vector temperatures, suggesting that this factor may have a role during mammalian infection., Importance: Yersinia pestis transitions from low-temperature residence and replication in insect vectors to higher-temperature replication in mammalian hosts. Prior findings based primarily on an avirulent derivative of WT (wild-type) KIM, named KIM6+, showed that biofilm formation associated with synthesis of poly-N-acetylglucosamine (PNAG) is maximal at 21 to 28°C and decreased at 37°C. Biofilm formation was purported to facilitate the transmission of Y. pestis from fleas to mammals while having little importance in mammalian infection. Here we found that for WT strains KIM and CO92, maximal PNAG production occurs at 37°C, indicating that temperature regulation of PNAG production in WT Y. pestis is not mimicked by strain KIM6+. Additionally, we found that Congo red binding does not always correlate with PNAG production, despite its widespread use as an indicator of biofilm production. Taken together, the findings show that a role for PNAG in WT Y. pestis infection should not be disregarded and warrants further study.
- Published
- 2012
- Full Text
- View/download PDF
37. Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection.
- Author
-
Skurnik D, Davis MR Jr, Benedetti D, Moravec KL, Cywes-Bentley C, Roux D, Traficante DC, Walsh RL, Maira-Litràn T, Cassidy SK, Hermos CR, Martin TR, Thakkallapalli EL, Vargas SO, McAdam AJ, Lieberman TD, Kishony R, Lipuma JJ, Pier GB, Goldberg JB, and Priebe GP
- Subjects
- Animals, Antibodies, Bacterial administration & dosage, Blood Bactericidal Activity, Burkholderia cepacia complex immunology, Disease Models, Animal, Female, Immunotherapy methods, Mice, Phagocytosis, Antibodies, Bacterial immunology, Burkholderia Infections therapy, Burkholderia cepacia complex drug effects, Polysaccharides, Bacterial immunology
- Abstract
Background: New therapeutic targets for antibiotic-resistant bacterial pathogens are desperately needed. The bacterial surface polysaccharide poly-β-(1-6)-N-acetyl-glucosamine (PNAG) mediates biofilm formation by some bacterial species, and antibodies to PNAG can confer protective immunity. By analyzing sequenced genomes, we found that potentially multidrug-resistant bacterial species such as Klebsiella pneumoniae, Enterobacter cloacae, Stenotrophomonas maltophilia, and the Burkholderia cepacia complex (BCC) may be able to produce PNAG. Among patients with cystic fibrosis patients, highly antibiotic-resistant bacteria in the BCC have emerged as problematic pathogens, providing an impetus to study the potential of PNAG to be targeted for immunotherapy against pan-resistant bacterial pathogens., Methods: The presence of PNAG on BCC was assessed using a combination of bacterial genetics, microscopy, and immunochemical approaches. Antibodies to PNAG were tested using opsonophagocytic assays and for protective efficacy against lethal peritonitis in mice., Results: PNAG is expressed in vitro and in vivo by the BCC, and cystic fibrosis patients infected by the BCC species B. dolosa mounted a PNAG-specific opsonophagocytic antibody response. Antisera to PNAG mediated opsonophagocytic killing of BCC and were protective against lethal BCC peritonitis even during coinfection with methicillin-resistant Staphylococcus aureus., Conclusions: Our findings raise potential new therapeutic options against PNAG-producing bacteria, including even pan-resistant pathogens.
- Published
- 2012
- Full Text
- View/download PDF
38. Synthesis and evaluation of a conjugate vaccine composed of Staphylococcus aureus poly-N-acetyl-glucosamine and clumping factor A.
- Author
-
Maira-Litrán T, Bentancor LV, Bozkurt-Guzel C, O'Malley JM, Cywes-Bentley C, and Pier GB
- Subjects
- Animals, Antibodies, Bacterial immunology, Antibody Specificity immunology, Bacteremia immunology, Chromatography, Gel, Cytotoxicity, Immunologic, Disease Models, Animal, Female, Fibrinogen metabolism, Goats immunology, Immobilized Proteins metabolism, Immune Sera immunology, Macaca mulatta immunology, Mice, Microscopy, Confocal, Models, Immunological, Opsonin Proteins metabolism, Phagocytes immunology, Rabbits, Staphylococcal Infections immunology, Staphylococcal Infections microbiology, Staphylococcal Infections prevention & control, Acetylglucosamine chemical synthesis, Acetylglucosamine immunology, Coagulase chemical synthesis, Coagulase immunology, Staphylococcus aureus immunology, Vaccines, Conjugate immunology
- Abstract
The increasing frequency, severity and antimicrobial resistance of Staphylococcus aureus infections has made the development of immunotherapies against this pathogen more urgent than ever. Previous immunization attempts using monovalent antigens resulted in at best partial levels of protection against S. aureus infection. We therefore reasoned that synthesizing a bivalent conjugate vaccine composed of two widely expressed antigens of S. aureus would result in additive/synergetic activities by antibodies to each vaccine component and/or in increased strain coverage. For this we used reductive amination, to covalently link the S. aureus antigens clumping factor A (ClfA) and deacetylated poly-N-β-(1-6)-acetyl-glucosamine (dPNAG). Mice immunized with 1, 5 or 10 µg of the dPNAG-ClfA conjugate responded in a dose-dependent manner with IgG to dPNAG and ClfA, whereas mice immunized with a mixture of ClfA and dPNAG developed significantly lower antibody titers to ClfA and no antibodies to PNAG. The dPNAG-ClfA vaccine was also highly immunogenic in rabbits, rhesus monkeys and a goat. Moreover, affinity-purified, antibodies to ClfA from dPNAG-ClfA immune serum blocked the binding of three S. aureus strains to immobilized fibrinogen. In an opsonophagocytic assay (OPKA) goat antibodies to dPNAG-ClfA vaccine, in the presence of complement and polymorphonuclear cells, killed S. aureus Newman and, to a lower extent, S. aureus Newman ΔclfA. A PNAG-negative isogenic mutant was not killed. Moreover, PNAG antigen fully inhibited the killing of S. aureus Newman by antisera to dPNAG-ClfA vaccine. Finally, mice passively vaccinated with goat antisera to dPNAG-ClfA or dPNAG-diphtheria toxoid conjugate had comparable levels of reductions of bacteria in the blood 2 h after infection with three different S. aureus strains as compared to mice given normal goat serum. In conclusion, ClfA is an immunogenic carrier protein that elicited anti-adhesive antibodies that fail to augment the OPK and protective activities of antibodies to the PNAG cell surface polysaccharide.
- Published
- 2012
- Full Text
- View/download PDF
39. Capsular polysaccharide masks clumping factor A-mediated adherence of Staphylococcus aureus to fibrinogen and platelets.
- Author
-
Risley AL, Loughman A, Cywes-Bentley C, Foster TJ, and Lee JC
- Subjects
- Bacterial Adhesion genetics, Coagulase genetics, Flow Cytometry, Humans, Microscopy, Confocal, Bacterial Adhesion physiology, Bacterial Capsules chemistry, Blood Platelets microbiology, Coagulase antagonists & inhibitors, Coagulase metabolism, Fibrinogen metabolism, Polysaccharides, Bacterial biosynthesis, Staphylococcus aureus pathogenicity
- Abstract
Background: Clumping factor A (ClfA) is a Staphylococcus aureus cell wall-associated adhesin that mediates staphylococcal binding to fibrinogen and platelets. Our goals were to determine whether expression of capsular polysaccharide (CP) affected ClfA-mediated adherence of S. aureus and to assess whether the length of the ClfA repeat region influenced this interaction., Methods: ClfA constructs with repeat regions of different lengths were introduced into isogenic S. aureus strains that expressed CP5, CP8, or no CP. S. aureus binding to fibrinogen was assessed in rabbit plasma and on fibrinogen-coated microtiter plates. Adherence of S. aureus strains to platelets was evaluated by flow cytometry and confocal microscopy., Results: As the length of the ClfA repeat region increased, binding of acapsular S. aureus to fibrinogen-coated microtiter plates was enhanced. By contrast, encapsulated S. aureus expressing the full-length ClfA were poorly adherent. The acapsular S. aureus mutant strain showed a 2-fold increase in platelet binding, compared with the isogenic encapsulated strains. By contrast, platelet aggregation was unaffected by CP production., Conclusion: CP expression inhibits S. aureus ClfA-mediated binding to fibrinogen and platelets, and a full-length repeat region cannot overcome this inhibition. These findings have important implications for vaccine development, given that CP may mask surface adhesins.
- Published
- 2007
- Full Text
- View/download PDF
40. Hyaluronic acid binding peptides prevent experimental staphylococcal wound infection.
- Author
-
Zaleski KJ, Kolodka T, Cywes-Bentley C, McLoughlin RM, Delaney ML, Charlton BT, Johnson W, and Tzianabos AO
- Subjects
- Amino Acid Sequence, Animals, Anti-Bacterial Agents metabolism, Colony Count, Microbial, Dose-Response Relationship, Drug, Methicillin Resistance, Mice, Mice, Inbred C57BL, Microbial Sensitivity Tests, Molecular Sequence Data, Peptides metabolism, Protein Binding, Staphylococcal Infections microbiology, Staphylococcal Infections pathology, Staphylococcus aureus drug effects, Surgical Wound Infection microbiology, Surgical Wound Infection pathology, Anti-Bacterial Agents therapeutic use, Hyaluronic Acid metabolism, Peptides therapeutic use, Staphylococcal Infections prevention & control, Surgical Wound Infection prevention & control
- Abstract
Staphylococcus aureus is a major cause of surgical wound infections. The development of mechanisms of antimicrobial resistance by this and other bacterial pathogens has prompted the search for new approaches to treat infectious diseases. Hyaluronic acid binding peptides have been shown to modulate cellular trafficking during host responses and were assessed for their ability to treat and possibly prevent experimental surgical wound infections caused by S. aureus. Treatment with these peptides was highly efficacious in reducing the number of S. aureus cells at the wound site and ameliorated the inflammatory host response associated with these infections. These data suggest a novel approach for the treatment and prophylaxis of staphylococcal wound infections in the clinical setting.
- Published
- 2006
- Full Text
- View/download PDF
41. Emergence of a bacterial clone with enhanced virulence by acquisition of a phage encoding a secreted phospholipase A2.
- Author
-
Sitkiewicz I, Nagiec MJ, Sumby P, Butler SD, Cywes-Bentley C, and Musser JM
- Subjects
- Animals, Bacteriophages pathogenicity, Cells, Cultured, Humans, Immunization, Male, Membrane Fusion, Mice, Phospholipases A genetics, Phospholipases A immunology, Phospholipases A2, Respiratory Tract Infections enzymology, Respiratory Tract Infections microbiology, Respiratory Tract Infections pathology, Streptococcal Infections immunology, Streptococcal Infections pathology, Streptococcus genetics, Survival Rate, Bacteriophages genetics, Phospholipases A metabolism, Streptococcal Infections enzymology, Streptococcal Infections microbiology, Streptococcus enzymology, Streptococcus pathogenicity
- Abstract
The molecular basis of pathogen clone emergence is relatively poorly understood. Acquisition of a bacteriophage encoding a previously unknown secreted phospholipase A(2) (designated SlaA) has been implicated in the rapid emergence in the mid-1980s of a new hypervirulent clone of serotype M3 group A Streptococcus. Although several lines of circumstantial evidence suggest that SlaA is a virulence factor, this issue has not been addressed experimentally. We found that an isogenic DeltaslaA mutant strain was significantly impaired in ability to adhere to and kill human epithelial cells compared with the wild-type parental strain. The mutant strain was less virulent for mice than the wild-type strain, and immunization with purified SlaA significantly protected mice from invasive disease. Importantly, the mutant strain was significantly attenuated for colonization in a monkey model of pharyngitis. We conclude that transductional acquisition of the ability of a GAS strain to produce SlaA enhanced the spread and virulence of the serotype M3 precursor strain. Hence, these studies identified a crucial molecular event underlying the evolution, rapid emergence, and widespread dissemination of unusually severe human infections caused by a distinct bacterial clone.
- Published
- 2006
- Full Text
- View/download PDF
42. Extracellular group A Streptococcus induces keratinocyte apoptosis by dysregulating calcium signalling.
- Author
-
Cywes Bentley C, Hakansson A, Christianson J, and Wessels MR
- Subjects
- Bacterial Capsules physiology, Bacterial Proteins toxicity, Boron Compounds pharmacology, Cell Line, Cytoplasm ultrastructure, DNA Fragmentation, Endoplasmic Reticulum ultrastructure, Humans, Hyaluronan Receptors metabolism, In Situ Nick-End Labeling, Mitochondria physiology, Mitochondria ultrastructure, Permeability, Streptococcus pyogenes metabolism, Streptolysins toxicity, Vacuoles ultrastructure, Apoptosis, Calcium metabolism, Calcium Signaling, Keratinocytes cytology, Keratinocytes microbiology, Streptococcus pyogenes pathogenicity
- Abstract
Group A Streptococcus (GAS) colonizes the oropharynx and damaged skin. To cause local infection or severe invasive syndromes the bacteria must gain access into deeper tissues. Host cell death may facilitate this process. GAS internalization has been identified to induce apoptosis. We now report an alternate mechanism of GAS-mediated apoptosis of primary human keratinocytes, initiated by extracellular GAS and involving dysregulation of intracellular calcium to produce endoplasmic reticulum stress. Two bacterial virulence factors are required for effective induction of apoptosis by extracellular GAS: (i) hyaluronic acid capsule that inhibits bacterial internalization and (ii) secreted cytolysin, streptolysin O (SLO), that forms transmembrane pores that permit extracellular calcium influx into the cytosol. Induction of keratinocyte apoptosis by wild-type GAS was accompanied by cell detachment and loss of epithelial integrity, a phenomenon not observed with GAS deficient in capsule or SLO. We propose that cell signalling initiated by extracellular GAS compromises the epithelial barrier by inducing premature keratinocyte differentiation and apoptosis, thereby facilitating GAS invasion of deeper tissues.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.